Get started

Medtronic

Medtronic leverages AI to enhance medical device developmentMedtronic Plc, a leading global medical device manufacturer, increasingly integrates artificial intelligence (AI) into its operations to enhance business efficiency and spearhead new developments. The company has positioned AI as a central element of its research and development strategy, employing machine learning algorithms to expedite the design and testing phases of new medical devices. The application of such AI solutions spans various functions, from optimising materials and device geometry to validating product performance via virtual simulations. Although Medtronic projects single-digit revenue growth for 2025, the escalating global demand for healthcare products may lead to more substantial growth. Exploring potential trading opportunities, let's analyse the stock chart of Medtronic Plc (NYSE: MDT) from a technical analysis perspective: On the Daily (D1) timeframe, Medtronic's stock has established a resistance level at 84.20 USD and support at 81.75 USD. An initial uptrend is evident, indicating the potential for further increases. However, if a downtrend starts, the downside target could be set at 70.10 USD. If the current uptrend continues and the stock price breaks through the resistance at 84.20 USD, there could be a buying opportunity with a short-term target of 89.30 USD. For those considering a medium-term investment strategy, the stock price might rise to 95.50 USD if the positive momentum persists. __ Ideas and other content presented on this page should not be considered as guidance for trading or an investment advice. RoboMarkets bears no responsibility for trading results based on trading opinions described in these analytical reviews. The material presented and the information contained herein is for information purposes only and in no way should be considered as the provision of investment advice for the purposes of Investment Firms Law L. 87(I)/2017 of the Republic of Cyprus or any other form of personal advice or recommendation, which relates to certain types of transactions with certain types of financial instruments. Risk Warning: CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69.88% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
NYSE:MDT
by RoboMarkets
Medtronic Beats Fourth-Quarter Estimates But Shares Down 2.44%Medtronic ( NYSE:MDT ), a health tech firm, has beat Wall Street estimates for quarterly profit and revenue in Q4 due to a pickup in surgical volumes at hospitals. The company's financial performance has grown due to a resurgence in demand as people, especially older adults, opted for medical procedures deferred during the COVID-19 pandemic. Medtronic forecasts fiscal 2025 adjusted per-share profit in the range of $5.40 to $5.50, with its midpoint in line with analysts' average estimate of $5.45. Medtronic ( NYSE:MDT ) joins medical device makers such as Abbott Laboratories and Boston Scientific that have also benefited from soaring demand for non-urgent surgeries. The company took an adjusted charge of $439 million in the fourth quarter, higher than its previously disclosed estimate of between $350 million and $425 million, related to its decision to exit its unprofitable ventilator product line and reorganize the respiratory and patient monitoring businesses. Sales at the company's diabetes unit, which returned to growth in the U.S. last quarter, rose 10.9% in the quarter ended April 26. However, sales at Medtronic's heart devices unit, its biggest revenue driver, fell 5.2% to $3.13 billion, missing analysts' estimate of $3.14 billion. The second-biggest unit by revenue, neuroscience, which makes medical devices and implants used in the treatment of the spine and musculoskeletal system, posted a 5.6% rise in sales, topping analysts' expectations. Medtronic ( NYSE:MDT ) reported Q4 worldwide revenue of $8.589 billion, an increase of 0.5% as reported and 5.4% on an organic basis. The organic revenue results reflect broad-based growth across the company, with mid-single digit or higher organic revenue growth in all four segments. FY24 worldwide revenue of $32.364 billion, an increase of 3.6% as reported and 5.2% on an organic basis, was reported. The company's momentum is building into the new fiscal year, with new product cycles in some of MedTech's most attractive markets and enhanced as AI is applied across the portfolio. Technical Outlook Despite profit beat, Medtronic ( NYSE:MDT ) stock is down 2.44% as of the time of writing trading with a Relative Strength Index (RSI) of 52.24 which is poised for a trend reversal in the near to long term. The daily price charts depicts a long wick Doji which means indecision among buyers and sellers.
NYSE:MDT
by DEXWireNews
MDT Medtronic plc Options Ahead of EarningsIf you haven`t bought the previous dip in MDT: Then analyzing the options chain and the chart patterns of MDT Medtronic plc prior to the earnings report this week, I would consider purchasing the 75usd strike price at the money Calls with an expiration date of 2023-11-24, for a premium of approximately $1.24. If these options prove to be profitable prior to the earnings release, I would sell at least half of them. Looking forward to read your opinion about it.
NYSE:MDTLong
by TopgOptions
Medtronic - C Wave in upgoing Zigzag. MDTGoals 199, 190, 185. Invalidation at 230. We are not in the business of getting every prediction right, no one ever does and that is not the aim of the game. The Fibonacci targets are highlighted in green with invalidation in red. Fibonacci goals, it is prudent to suggest, are nothing more than mere fractally evident and therefore statistically likely levels that the market will go to. Having said that, the market will always do what it wants and always has a mind of its own. Therefore, none of this is financial advice, so do your own research and rely only on your own analysis. Trading is a true one man sport. Good luck out there and stay safe
NYSE:MDTLong
by Rykin_Capital
Piggyback the profiteers After some conversation with a young single mom and what she goes through to get her and her 2 yr old diabetes meds @ $13hr...f to the big pharma and f to the health care that does not cover such a life saving drug. It's not a conspiracy...it's a cultural failure to recognize how far we have come in such a short time. Some will call it profiteering...sure but it's also about what is done with those profits...what could be done. So I'm in on medtronic with the mission to take their pillaging and raping of the target audience, get some profits and help someone that needs help with their medication. www.diabetes.ca you can donate as well....I just want to take the strain off someone I know personally.
NYSE:MDT
by Honkytime
Using $TRXC info to guide $TMDI decisionNASDAQ:TMDI AMEX:TRXC These symbols have been on a similar path throughout the year. From November to the beginning of January, $TRXC price action lagged a few days behind $TMDI. Since January $TMDI appears to be the follower. Watching price action of $TRXC when it reaches the yellow ellipse may give us an idea of how $TMDI will eventually exit this channel. May be a good spot for a short-term swing trade. Thanks for looking!
TLong
by excitedOil3295
Bull Flag&Breakout For Medtronic Plc Just Another Reason To LongMedtronic Plc has recently agreed to acquire all outstanding shares of spinal surgery device maker, Medicrea at €7.00/share, representing a 22% premium over Friday's closing price. This merger and acquisition has driven the share price to move up as well as giving the stock a promising future amidst the advent of second wave of the pandemic which most of the analysts foresee the economy to be worse than before. Key Trading Plan: Since the price has broken the trend line, wait for pull back to the support level of 94.67, and LONG the stock with the Take Profit Target of 104.88 (Key Resistance Level). ‼️Disclaimer: Please be advised that we are NOT Financial Advisors. We are not responsible for the results of your Forex or CFDs trading. The only person responsible for profits or losses is yourself. You should not consider any market information, educational and analytical material as trading advice that defines your trading actions but purely as educational market material. Please be advised that S.I.D. Capital shall not be liable for any errors in quotes and trading platform software errors. ‼️This Channel and all information is intended for educational purposes only and does not give financial advice. S.I.D. Capital Signals is not a service to provide legal and financial advice; any information provided here is only the personal opinion of the author (not advice or financial advice in any sense, and in the sense of any act, ordinance or law of any country) and must not be used for financial activities.
NYSE:MDTLong
by SIDCapital
Medical devices will winHealthcare has been a leader YTD, as it has the defensive nature and is gaining momentum on the spread and containment of the COVID. Also, negative sentiment of the healthcare sector regarding the opioid crisis (which seems like a long time ago now), and politicians creating regulations for insurance reform; has now subsided. Inside the XLV, IHI (medical devices) and IBB (Biotechnology) have been outperforming, and will likely continue to do so. The 3 most important holdings of the ETF will be very important during this pandemic: 1. ABT (diagnostic test for COVID) / 12.63% 2. MDT (medical ventilators/respirators) / 12.52% 3. TMO (diagnostic test for COVID) / 10.82%
AMEX:IHILong
by dorfmanmaster
Is this stock worth owning?Medtronic plc develops, manufactures, distributes, and sells device-based medical therapies to hospitals, physicians, clinicians, and patients worldwide. It operates through four segments: Cardiac and Vascular Group, Minimally Invasive Therapies Group, Restorative Therapies Group, and Diabetes Group. The Cardiac and Vascular Group segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; AF ablation product; insertable cardiac monitor systems; mechanical circulatory support; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves; percutaneous coronary intervention stents, surgical valve replacement and repair products, endovascular stent grafts, percutaneous angioplasty balloons, and products to treat superficial venous diseases in the lower extremities. The Minimally Invasive Therapies Group segment offers surgical products, including surgical stapling devices, vessel sealing instruments, wound closure, electrosurgery products, hernia mechanical devices, mesh implants, and gynecology products; hardware instruments and mesh fixation device; and gastrointestinal, inhalation therapy, and renal care solutions. The Restorative Therapies Group segment offers products for spinal surgeons, neurosurgeons, neurologists, pain management specialists, anesthesiologists, orthopedic surgeons, urologists, colorectal surgeons, urogynecologists, interventional radiologists, and ear, nose, and throat specialists; and systems that incorporate energy surgical instruments. It also provides image-guided surgery and intra-operative imaging systems; and therapies for vasculature in and around the brain. The Diabetes Group segment offers insulin pumps and consumables, continuous glucose monitoring systems, and therapy management software. The company was founded in 1949 and is headquartered in Dublin, Ireland.
NYSE:MDT
by Skinwah